Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023

BACKGROUND: Patients with bladder cancer (BC) who are cisplatin ineligible or have unresectable disease have limited treatment options. Previously, we showed targeting programmed death-ligand 1 (PD-L1) with durvalumab (durva) and radiation therapy (RT) combination was safe in BC. We now report resul...

Descripción completa

Detalles Bibliográficos
Autores principales: Joshi, Monika, Tuanquin, Leonard, Zhu, Junjia, Walter, Vonn, Schell, Todd, Kaag, Matthew, Kilari, Deepak, Liao, Jiangang, Holder, Sheldon L, Emamekhoo, Hamid, Sankin, Alexander, Merrill, Suzzane, Zheng, Hong, Warrick, Joshua, Hauke, Ralph, Gartrel, Benjamin, Stein, Mark, Drabick, Joseph, Degraff, David J, Zakharia, Yousef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950974/
https://www.ncbi.nlm.nih.gov/pubmed/36822667
http://dx.doi.org/10.1136/jitc-2022-006551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950974/
https://www.ncbi.nlm.nih.gov/pubmed/36822667
http://dx.doi.org/10.1136/jitc-2022-006551

Ejemplares similares